PHIAA Stock Overview
Operates as a health technology company in North America, the Greater China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Koninklijke Philips N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €24.46 |
| 52 Week High | €30.16 |
| 52 Week Low | €17.57 |
| Beta | 0.79 |
| 11 Month Change | -18.18% |
| 3 Month Change | -7.59% |
| 1 Year Change | 30.94% |
| 33 Year Change | -24.16% |
| 5 Year Change | -36.45% |
| Change since IPO | 86.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHIAA | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -1.9% | 7.7% | -0.4% |
| 1Y | 30.9% | -2.1% | 5.6% |
Return vs Industry: PHIAA exceeded the UK Medical Equipment industry which returned -2.1% over the past year.
Return vs Market: PHIAA exceeded the UK Market which returned 5.6% over the past year.
Price Volatility
| PHIAA volatility | |
|---|---|
| PHIAA Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PHIAA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: PHIAA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 68,701 | Roy Jakobs | www.philips.com |
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Koninklijke Philips N.V. Fundamentals Summary
| PHIAA fundamental statistics | |
|---|---|
| Market cap | €22.94b |
| Earnings (TTM) | -€469.00m |
| Revenue (TTM) | €18.04b |
1.3x
P/S Ratio-48.9x
P/E RatioIs PHIAA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHIAA income statement (TTM) | |
|---|---|
| Revenue | €18.04b |
| Cost of Revenue | €10.43b |
| Gross Profit | €7.61b |
| Other Expenses | €8.08b |
| Earnings | -€469.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 42.18% |
| Net Profit Margin | -2.60% |
| Debt/Equity Ratio | 69.4% |
How did PHIAA perform over the long term?
See historical performance and comparison